[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026",
    "summary": "Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=598df7049377e0fe4c94065e6eabf54853a35b89d0257c8ec8a6dd09bab40b87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770395977,
      "headline": "Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026",
      "id": 138379417,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252188756/image_2252188756.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=598df7049377e0fe4c94065e6eabf54853a35b89d0257c8ec8a6dd09bab40b87"
    }
  },
  {
    "ts": null,
    "headline": "What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)?",
    "summary": "Recent updates around Bristol Myers Squibb have nudged the fair value estimate to US$58.13 from US$56.26, a modest shift that reflects refreshed assumptions on risk, revenue trends, and how much of the 2026 pipeline potential is being recognized in current pricing. Street research sits in a mixed but generally constructive zone, with some analysts pointing to a busy calendar of upcoming data and others stressing that execution questions and already cautious expectations still matter. Read on...",
    "url": "https://finnhub.io/api/news?id=bb14688cb9450599efc51202e631cd455840fd4865709aef8fcc8c4b33505307",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770390544,
      "headline": "What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)?",
      "id": 138375549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recent updates around Bristol Myers Squibb have nudged the fair value estimate to US$58.13 from US$56.26, a modest shift that reflects refreshed assumptions on risk, revenue trends, and how much of the 2026 pipeline potential is being recognized in current pricing. Street research sits in a mixed but generally constructive zone, with some analysts pointing to a busy calendar of upcoming data and others stressing that execution questions and already cautious expectations still matter. Read on...",
      "url": "https://finnhub.io/api/news?id=bb14688cb9450599efc51202e631cd455840fd4865709aef8fcc8c4b33505307"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.",
    "summary": "Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.",
    "url": "https://finnhub.io/api/news?id=b333ab0a1768a7c0b038f5a2025627fbe7007ba878dd3d68bf1de6c88555bea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770381300,
      "headline": "Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.",
      "id": 138374484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.",
      "url": "https://finnhub.io/api/news?id=b333ab0a1768a7c0b038f5a2025627fbe7007ba878dd3d68bf1de6c88555bea2"
    }
  },
  {
    "ts": null,
    "headline": "BMS reports flat revenue growth for full-year 2025",
    "summary": "The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.",
    "url": "https://finnhub.io/api/news?id=eaf469bcdbdc3c2bb77d0f28b3bff0e571a3c5ef2a9f31f43877a219b66b1403",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770378503,
      "headline": "BMS reports flat revenue growth for full-year 2025",
      "id": 138374485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.",
      "url": "https://finnhub.io/api/news?id=eaf469bcdbdc3c2bb77d0f28b3bff0e571a3c5ef2a9f31f43877a219b66b1403"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Q4 Earnings Call Highlights",
    "summary": "Bristol Myers Squibb (NYSE:BMY) executives emphasized “focused execution” in 2025 and pointed to continued momentum entering 2026, as the company’s growth portfolio increasingly offsets declines in legacy products. On the company’s fourth-quarter earnings call, management highlighted strong contribu",
    "url": "https://finnhub.io/api/news?id=1cff7387c4f6ddf03d1c419a1af90e3089e76ce6375d3d8750984db21a7ad14c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770370047,
      "headline": "Bristol Myers Squibb Q4 Earnings Call Highlights",
      "id": 138372994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (NYSE:BMY) executives emphasized “focused execution” in 2025 and pointed to continued momentum entering 2026, as the company’s growth portfolio increasingly offsets declines in legacy products. On the company’s fourth-quarter earnings call, management highlighted strong contribu",
      "url": "https://finnhub.io/api/news?id=1cff7387c4f6ddf03d1c419a1af90e3089e76ce6375d3d8750984db21a7ad14c"
    }
  },
  {
    "ts": null,
    "headline": "BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 4.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=fa2e7848c8766a7adec1d1f977060d9fcbc3f95a2bdbb9ad6505b985a25a9be5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770356088,
      "headline": "BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus",
      "id": 138373627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 4.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=fa2e7848c8766a7adec1d1f977060d9fcbc3f95a2bdbb9ad6505b985a25a9be5"
    }
  },
  {
    "ts": null,
    "headline": "Trump Touts Drug Cost Savings as He Launches TrumpRx Website",
    "summary": "“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers through a new website, TrumpRx.gov,” Trump said at a White House event Thursday to hail the new effort.  The administration has touted its efforts to lower the cost of drugs, including by negotiating agreements with more than a dozen of the world’s largest pharmaceutical companies, including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc., often in exchange for a reduction in threatened tariffs.",
    "url": "https://finnhub.io/api/news?id=c496ddde896a4d1d2328e83f71a269d47448c874a6e4923a97f8eebaa6565d44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770339419,
      "headline": "Trump Touts Drug Cost Savings as He Launches TrumpRx Website",
      "id": 138376813,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers through a new website, TrumpRx.gov,” Trump said at a White House event Thursday to hail the new effort.  The administration has touted its efforts to lower the cost of drugs, including by negotiating agreements with more than a dozen of the world’s largest pharmaceutical companies, including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc., often in exchange for a reduction in threatened tariffs.",
      "url": "https://finnhub.io/api/news?id=c496ddde896a4d1d2328e83f71a269d47448c874a6e4923a97f8eebaa6565d44"
    }
  }
]